Seeking Alpha
08 Jun 2026, 09:27 UTC · 13w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
enGene Therapeutics' sole asset, detalimogene voraplasmid, showed a low 12-month complete response rate of 25% in Phase 2 trials, underperforming competitors. — Low efficacy for a company's only asset significantly increases the risk of FDA rejection and poor commercial viability.
-0.80The company is currently trading below its cash floor of $4.66 per share. — Trading below the cash-per-share value typically provides a fundamental floor that limits further downside risk.
+0.60Detalimogene voraplasmid has been granted Fast Track and RMAT status by the FDA. — Regulatory designations can accelerate the approval process and indicate a perceived unmet medical need.
+0.30Continue reading
5 related stories
Search tags
The therapy demonstrates a strong safety profile. — Strong safety data reduces the risk of clinical holds or severe regulatory hurdles, though it is secondary to efficacy.
Which stocks this story touches
Weak Phase 2 data and low efficacy rates are weighed against a strong cash position and a Buy rating.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
11h ago
